Francesca Mallamaci
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Francesca Mallamaci has a total of 153 co-authors. Here are the top co-authors by number of shared publications:
- Carmine Zoccali
Institute of Molecular Biology and Genetics (Biogem), Ariano Irpino, Italy
19 shared publications Giovanni Tripepi
Clinical Epidemiology Unit, CNR Institute of Clinical Physiology, Reggio Calabria, Italy
4 shared publications- Claudia Torino
Institute of Clinical Physiology, National Research Council - Reggio Calabria Unit, Reggio Calabria, RC, Italy
3 shared publications Rocco Tripepi
IFC-CNR, REGGIO CALABRIA, Reggio Calabria, Italy
3 shared publications- Daniela Leonardis
SantAnna School of Advanced Studies,Department of Excellence in Robotics and AI,Pisa,Italy,56127
2 shared publications - Ferruccio Galletti
Department of Clinical Medicine and Surgery, “Federico II” University of Naples Medical School, 80131 Naples, Italy
2 shared publications
Latest Publications
- Open Access
- 25 October 2026
- Published by Wiley in Journal of Internal Medicine
One estimated glomerular filtration rate, many diseases: What remains beyond filtration‐based classification of chronic kidney disease?
Estimated glomerular filtration rate (eGFR) is indispensable for detecting, staging, prognosticating, and managing chronic kidney disease (CKD), but it measures filtration rather than defining the underlying disease. A reduced eGFR can reflect many different processes, including nephron loss, altered renal hemodynamics, glomerular injury, tubulointerstitial disease, vascular damage, congenital abnormalities, obstruction, systemic inflammation, recurrent acute kidney injury, or combinations of these mechanisms. Thus, patients with the same eGFR may have different kidneys, diseases, trajectories, prognoses, and treatment opportunities. Current CKD classification already incorporates cause, GFR category, and albuminuria category, but in clinical practice and research eGFR often remains disproportionately influential in language, referral pathways, trial eligibility, and treatment decisions. This simplification can obscure active or treatable disease, encourage over‐investigation of stable vascular or age‐related impairment, and create biologically heterogeneous trial populations that dilute treatment effects. Albuminuria substantially improves risk stratification, but it does not by itself define disease phenotype or mechanism. This review argues for broader implementation of the cause–GFR–albuminuria framework and for interpreting eGFR within a broader clinical and biological phenotype. A more comprehensive assessment should integrate albuminuria or proteinuria, urine sediment, longitudinal eGFR and albuminuria trajectories, hemodynamic context, medication and nephrotoxin exposure, systemic features, family history, kidney imaging, and targeted use of cystatin C, serology, monoclonal protein testing, genetic testing, kidney biopsy, and molecular biomarkers when clinically appropriate. The aim is not to replace eGFR but to place it in context. Precision nephrology will depend on distinguishing filtration level from disease identity, activity, chronicity, reversibility, and treatment responsiveness.
- 25 October 2026
- Published by Wiley in Journal of Internal Medicine
Open AccessOne estimated glomerular filtration rate, many diseases: What remains beyond filtration‐based classification of chronic kidney disease?
Estimated glomerular filtration rate (eGFR) is indispensable for detecting, staging, prognosticating, and managing chronic kidney disease (CKD), but it measures filtration rather than defining the underlying disease. A reduced eGFR can reflect many different processes, including nephron loss, altered renal hemodynamics, glomerular injury, tubulointerstitial disease, vascular damage, congenital abnormalities, obstruction, systemic inflammation, recurrent acute kidney injury, or combinations of these mechanisms. Thus, patients with the same eGFR may have different kidneys, diseases, trajectories, prognoses, and treatment opportunities. Current CKD classification already incorporates cause, GFR category, and albuminuria category, but in clinical practice and research eGFR often remains disproportionately influential in language, referral pathways, trial eligibility, and treatment decisions. This simplification can obscure active or treatable disease, encourage over‐investigation of stable vascular or age‐related impairment, and create biologically heterogeneous trial populations that dilute treatment effects. Albuminuria substantially improves risk stratification, but it does not by itself define disease phenotype or mechanism. This review argues for broader implementation of the cause–GFR–albuminuria framework and for interpreting eGFR within a broader clinical and biological phenotype. A more comprehensive assessment should integrate albuminuria or proteinuria, urine sediment, longitudinal eGFR and albuminuria trajectories, hemodynamic context, medication and nephrotoxin exposure, systemic features, family history, kidney imaging, and targeted use of cystatin C, serology, monoclonal protein testing, genetic testing, kidney biopsy, and molecular biomarkers when clinically appropriate. The aim is not to replace eGFR but to place it in context. Precision nephrology will depend on distinguishing filtration level from disease identity, activity, chronicity, reversibility, and treatment responsiveness.
- 1 September 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83 (9)
Finerenone Plus Empagliflozin: How Low Can We Go, and How Much Does Blood Pressure Matter?
- 1 September 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83 (9)
Finerenone Plus Empagliflozin: How Low Can We Go, and How Much Does Blood Pressure Matter?
- 27 August 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
Microbiome Science and the Kidney–Vascular Axis
Was not provided for this article.
- 27 August 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
Microbiome Science and the Kidney–Vascular Axis
Was not provided for this article.
- Open Access
- 21 August 2026
- Published by Wiley in Journal of Internal Medicine
- Vol. 300 (5) , 553-571
Sudden cardiac death in chronic kidney disease and dialysis: From descriptive epidemiology to mechanism‐driven prevention
Sudden cardiac death (SCD) is a leading cause of mortality across the chronic kidney disease (CKD) continuum and becomes particularly prominent in dialysis‐dependent kidney failure. In hemodialysis, SCD accounts for roughly one quarter to one third of all deaths and up to 60%–75% of cardiovascular mortality, with marked temporal clustering around the long interdialytic interval and the first post‐interval session. Traditional views have emphasized descriptive epidemiology and presumed ventricular tachyarrhythmias. More recent device‐based studies challenge this paradigm, revealing a heterogeneous arrhythmic spectrum in which bradyarrhythmias, pauses, and conduction system disease are often at least as frequent as sustained ventricular tachycardia or fibrillation. This narrative, non‐systematic review synthesizes epidemiologic, mechanistic, and interventional data on SCD in CKD and dialysis, with particular emphasis on insights from implantable loop recorder and implantable cardioverter–defibrillator cohorts and on modifiable dialytic and pharmacologic factors. A framework for prevention is proposed around three interacting domains: the structural myocardial substrate, the electrophysiologic milieu, and dialysis‐related triggers. Within this framework, contemporary heart failure and CKD therapies (including sodium–glucose cotransporter 2 inhibitors, angiotensin receptor–neprilysin inhibitors, mineralocorticoid receptor antagonists, and beta‐blockers), individualized dialysis prescriptions (targeting potassium, calcium, bicarbonate, ultrafiltration, and scheduling), and selective use of device therapy are considered complementary components of mechanism‐driven SCD prevention. Methodological challenges in defining and adjudicating SCD in CKD are discussed, and priorities are outlined for improved phenotyping, continuous rhythm monitoring, and CKD‐specific risk stratification, with the overarching aim of moving from descriptive statistics to effective risk modification.
- 21 August 2026
- Published by Wiley in Journal of Internal Medicine
- Vol. 300 (5) , 553-571
Open AccessSudden cardiac death in chronic kidney disease and dialysis: From descriptive epidemiology to mechanism‐driven prevention
Sudden cardiac death (SCD) is a leading cause of mortality across the chronic kidney disease (CKD) continuum and becomes particularly prominent in dialysis‐dependent kidney failure. In hemodialysis, SCD accounts for roughly one quarter to one third of all deaths and up to 60%–75% of cardiovascular mortality, with marked temporal clustering around the long interdialytic interval and the first post‐interval session. Traditional views have emphasized descriptive epidemiology and presumed ventricular tachyarrhythmias. More recent device‐based studies challenge this paradigm, revealing a heterogeneous arrhythmic spectrum in which bradyarrhythmias, pauses, and conduction system disease are often at least as frequent as sustained ventricular tachycardia or fibrillation. This narrative, non‐systematic review synthesizes epidemiologic, mechanistic, and interventional data on SCD in CKD and dialysis, with particular emphasis on insights from implantable loop recorder and implantable cardioverter–defibrillator cohorts and on modifiable dialytic and pharmacologic factors. A framework for prevention is proposed around three interacting domains: the structural myocardial substrate, the electrophysiologic milieu, and dialysis‐related triggers. Within this framework, contemporary heart failure and CKD therapies (including sodium–glucose cotransporter 2 inhibitors, angiotensin receptor–neprilysin inhibitors, mineralocorticoid receptor antagonists, and beta‐blockers), individualized dialysis prescriptions (targeting potassium, calcium, bicarbonate, ultrafiltration, and scheduling), and selective use of device therapy are considered complementary components of mechanism‐driven SCD prevention. Methodological challenges in defining and adjudicating SCD in CKD are discussed, and priorities are outlined for improved phenotyping, continuous rhythm monitoring, and CKD‐specific risk stratification, with the overarching aim of moving from descriptive statistics to effective risk modification.
- 21 August 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
Artificial Intelligence Structural Biology in Nephrology
Artificial intelligence (AI)–based protein structure prediction has rapidly entered nephrology, providing plausible atomic models for channels, transporters, receptors, and scaffolds that previously lacked structural information. AlphaFold and RoseTTAFold currently underpin mechanistic interpretations of inherited kidney diseases, including autosomal dominant polycystic kidney disease, cystinosis, and Alport syndrome, and support experimental design in cryo-electron microscopy and cryo-electron tomography. For nephrologists, this means that renal proteins no longer need to be treated as black boxes: Genetic, biochemical, and physiologic data can at present be mapped onto concrete 3-dimensional scaffolds. However, the apparent precision of AI models can be misleading. Renal proteins frequently fall within underrepresented classes, including multipass membrane proteins, intrinsically disordered scaffolds, and human-specific isoforms with shallow multiple sequence alignments, where confidence scores may not accurately reflect model reliability. Current predictors typically deliver static snapshots, whereas transporters, channels, and slit-diaphragm complexes function as dynamic ensembles embedded in specific lipid and macromolecular environments. Attempts to use AlphaFold directly for variant classification or to estimate changes in thermodynamic stability or function show only modest agreement with mutagenesis data, particularly for gain-of-function and dominant-negative alleles that depend on subtle conformational and interaction changes. Common pitfalls include overinterpreting oligomeric stoichiometry inferred from AlphaFold Multimer, reading too much into domain orientations with high predicted aligned error, and dismissing low-confidence regions as modeling failures rather than recognizing intrinsically disordered, potentially regulatory segments. Integrative approaches combining cryo-ET, crosslinking mass spectrometry, and molecular dynamics can mitigate these limitations but remain labor intensive and low throughput. An explainable, hypothesis-driven use of AI that treats predicted structures as working scaffolds to be cross-validated against imaging, biophysics, and functional assays offers the most reliable path toward a genuinely mechanistic nephrology and responsible clinical translation of AI–based structural insights.
- 21 August 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
Artificial Intelligence Structural Biology in Nephrology
Artificial intelligence (AI)–based protein structure prediction has rapidly entered nephrology, providing plausible atomic models for channels, transporters, receptors, and scaffolds that previously lacked structural information. AlphaFold and RoseTTAFold currently underpin mechanistic interpretations of inherited kidney diseases, including autosomal dominant polycystic kidney disease, cystinosis, and Alport syndrome, and support experimental design in cryo-electron microscopy and cryo-electron tomography. For nephrologists, this means that renal proteins no longer need to be treated as black boxes: Genetic, biochemical, and physiologic data can at present be mapped onto concrete 3-dimensional scaffolds. However, the apparent precision of AI models can be misleading. Renal proteins frequently fall within underrepresented classes, including multipass membrane proteins, intrinsically disordered scaffolds, and human-specific isoforms with shallow multiple sequence alignments, where confidence scores may not accurately reflect model reliability. Current predictors typically deliver static snapshots, whereas transporters, channels, and slit-diaphragm complexes function as dynamic ensembles embedded in specific lipid and macromolecular environments. Attempts to use AlphaFold directly for variant classification or to estimate changes in thermodynamic stability or function show only modest agreement with mutagenesis data, particularly for gain-of-function and dominant-negative alleles that depend on subtle conformational and interaction changes. Common pitfalls include overinterpreting oligomeric stoichiometry inferred from AlphaFold Multimer, reading too much into domain orientations with high predicted aligned error, and dismissing low-confidence regions as modeling failures rather than recognizing intrinsically disordered, potentially regulatory segments. Integrative approaches combining cryo-ET, crosslinking mass spectrometry, and molecular dynamics can mitigate these limitations but remain labor intensive and low throughput. An explainable, hypothesis-driven use of AI that treats predicted structures as working scaffolds to be cross-validated against imaging, biophysics, and functional assays offers the most reliable path toward a genuinely mechanistic nephrology and responsible clinical translation of AI–based structural insights.
- 9 February 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (10) , 1826-1835
Cardiovascular Risk Assessment Tools in CKD
Cardiovascular (CV) risk calculators estimate the likelihood of CV events by integrating factors such as age, sex, BP, lipids, smoking, and diabetes. Commonly used tools in the general population include the Framingham Risk Score, Systematic Coronary Risk Evaluation, atherosclerotic cardiovascular disease Pooled Cohort Equations, and QResearch Cardiovascular Risk Algorithm (QRISK), the latter being regularly updated using large-scale UK health records and including a wider range of variables such as CKD. CKD is a strong, independent risk factor for CV disease, but most standard models omit kidney function and CKD-specific factors ( e.g ., inflammation, vascular calcification, and mineral metabolism disorders). Consequently, they often underestimate CV risk in CKD, particularly in advanced stages and among dialysis patients, where competing risks ( e.g ., non-CV death) further complicate risk estimation. To overcome these limitations, enhanced and CKD-specific models have been developed. Systematic Coronary Risk Evaluation Add-ons incorporate eGFR and albuminuria to refine prediction in CKD. QRISK includes CKD as a variable. The CKD Prognosis Consortium and Predicting Risk of Cardiovascular Disease EVENTs models are tailored to CKD populations and leverage large, diverse datasets to improve discrimination and calibration. Reflecting this evidence, the 2024 Kidney Disease Improving Global Outcomes guidelines recommend QRISK, CKD Prognosis Consortium, and Predicting Risk of Cardiovascular Disease EVENTs for CV risk prediction in CKD. Artificial intelligence and machine learning approaches may further enhance risk prediction by exploiting complex clinical and laboratory data, but they require external validation, transparency, and assessment of clinical utility before broad implementation. CV risk calculators should support, not replace, clinical judgment and must be embedded within individualized, multifactorial management strategies. This narrative review summarizes the main characteristics, strengths, and limitations of currently available CV risk tools for CKD, focusing on those endorsed by major international guidelines and used in routine practice. We adopt a global perspective, while acknowledging that most evidence derives from high-income settings, which limits generalizability.
- 9 February 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (10) , 1826-1835
Cardiovascular Risk Assessment Tools in CKD
Cardiovascular (CV) risk calculators estimate the likelihood of CV events by integrating factors such as age, sex, BP, lipids, smoking, and diabetes. Commonly used tools in the general population include the Framingham Risk Score, Systematic Coronary Risk Evaluation, atherosclerotic cardiovascular disease Pooled Cohort Equations, and QResearch Cardiovascular Risk Algorithm (QRISK), the latter being regularly updated using large-scale UK health records and including a wider range of variables such as CKD. CKD is a strong, independent risk factor for CV disease, but most standard models omit kidney function and CKD-specific factors ( e.g ., inflammation, vascular calcification, and mineral metabolism disorders). Consequently, they often underestimate CV risk in CKD, particularly in advanced stages and among dialysis patients, where competing risks ( e.g ., non-CV death) further complicate risk estimation. To overcome these limitations, enhanced and CKD-specific models have been developed. Systematic Coronary Risk Evaluation Add-ons incorporate eGFR and albuminuria to refine prediction in CKD. QRISK includes CKD as a variable. The CKD Prognosis Consortium and Predicting Risk of Cardiovascular Disease EVENTs models are tailored to CKD populations and leverage large, diverse datasets to improve discrimination and calibration. Reflecting this evidence, the 2024 Kidney Disease Improving Global Outcomes guidelines recommend QRISK, CKD Prognosis Consortium, and Predicting Risk of Cardiovascular Disease EVENTs for CV risk prediction in CKD. Artificial intelligence and machine learning approaches may further enhance risk prediction by exploiting complex clinical and laboratory data, but they require external validation, transparency, and assessment of clinical utility before broad implementation. CV risk calculators should support, not replace, clinical judgment and must be embedded within individualized, multifactorial management strategies. This narrative review summarizes the main characteristics, strengths, and limitations of currently available CV risk tools for CKD, focusing on those endorsed by major international guidelines and used in routine practice. We adopt a global perspective, while acknowledging that most evidence derives from high-income settings, which limits generalizability.
- 12 September 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (10) , 1321-1322
Addressing Sex Disparities in Coronary Revascularization among Dialysis Patients
- 12 September 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (10) , 1321-1322
Addressing Sex Disparities in Coronary Revascularization among Dialysis Patients
- 13 June 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (8) , 1072-1078
Sex Differences in the EXerCise Introduction to Enhance Performance in Dialysis Trial
Key Points: Inactivity in patients with ESKD worsens quality of life, function, and increases morbidity. Post hoc analysis of the EXerCise Introduction to Enhance Performance in Dialysis trial explores 6-month exercise effects in dialysis patients, stratified by sex. Sex-based findings may inform tailored interventions to enhance function and quality of life in patients with ESKD. Background: Physical inactivity in patients with ESKD is linked to poor quality of life, lower physical function, and higher morbidity. Promoting physical activity and improving performance is vital for their care. This post hoc analysis of the EXerCise Introduction to Enhance Performance in Dialysis trial examined the effects of a 6-month exercise program for dialysis patients stratified by sex. Methods: In the EXerCise Introduction to Enhance Performance in Dialysis trial participants were randomized into an exercise versus a control group. Eligible patients were recruited from 13 centers over November 2009–February 2011 and were followed for 36 months. This analysis focused on sex-stratified effects, including 227 dialysis patients (151 men, 76 women) who completed the 6-minute walking distance (6MWD) test and the five times sit-to-stand (5STS) test at baseline and after 6 months. The primary outcomes were changes in 6MWD and 5STS over a 6-month period. Data were analyzed using linear regression models to assess sex as an effect modifier. Results: Both male (+37.1 versus +12.6 m, P = 0.005) and female (+42.7 versus −18.5 m, P < 0.001) patients in the exercise group showed significant improvements in 6MWD compared with controls. In unadjusted (P = 0.02) and fully adjusted (P = 0.006) interaction analyses, the response to this test in women improved more than in men. In sex-stratified analyses, the between-group difference in the response to the 5STS was numerically larger in women (−2.5 versus +0.4 seconds, P = 0.007) than in men (−2.4 versus −1.2 seconds, P = 0.06), but this difference did not reach statistical significance in interaction analysis (unadjusted, P = 0.15; fully adjusted, P = 0.11). Conclusions: The exercise program improved physical performance in dialysis patients, with women showing more significant enhancements in 6MWD. These exploratory findings suggest that sex-specific physiologic differences may influence exercise outcomes in dialysis patients. Clinical Trial registry name and registration number: NCT01255969.
- 13 June 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (8) , 1072-1078
Sex Differences in the EXerCise Introduction to Enhance Performance in Dialysis Trial
Key Points: Inactivity in patients with ESKD worsens quality of life, function, and increases morbidity. Post hoc analysis of the EXerCise Introduction to Enhance Performance in Dialysis trial explores 6-month exercise effects in dialysis patients, stratified by sex. Sex-based findings may inform tailored interventions to enhance function and quality of life in patients with ESKD. Background: Physical inactivity in patients with ESKD is linked to poor quality of life, lower physical function, and higher morbidity. Promoting physical activity and improving performance is vital for their care. This post hoc analysis of the EXerCise Introduction to Enhance Performance in Dialysis trial examined the effects of a 6-month exercise program for dialysis patients stratified by sex. Methods: In the EXerCise Introduction to Enhance Performance in Dialysis trial participants were randomized into an exercise versus a control group. Eligible patients were recruited from 13 centers over November 2009–February 2011 and were followed for 36 months. This analysis focused on sex-stratified effects, including 227 dialysis patients (151 men, 76 women) who completed the 6-minute walking distance (6MWD) test and the five times sit-to-stand (5STS) test at baseline and after 6 months. The primary outcomes were changes in 6MWD and 5STS over a 6-month period. Data were analyzed using linear regression models to assess sex as an effect modifier. Results: Both male (+37.1 versus +12.6 m, P = 0.005) and female (+42.7 versus −18.5 m, P < 0.001) patients in the exercise group showed significant improvements in 6MWD compared with controls. In unadjusted (P = 0.02) and fully adjusted (P = 0.006) interaction analyses, the response to this test in women improved more than in men. In sex-stratified analyses, the between-group difference in the response to the 5STS was numerically larger in women (−2.5 versus +0.4 seconds, P = 0.007) than in men (−2.4 versus −1.2 seconds, P = 0.06), but this difference did not reach statistical significance in interaction analysis (unadjusted, P = 0.15; fully adjusted, P = 0.11). Conclusions: The exercise program improved physical performance in dialysis patients, with women showing more significant enhancements in 6MWD. These exploratory findings suggest that sex-specific physiologic differences may influence exercise outcomes in dialysis patients. Clinical Trial registry name and registration number: NCT01255969.
- 14 March 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (7) , 1000-1002
Autonomic Nervous System Dysregulation and Bone Health in Patients with CKD
An abstract is unavailable. This article is available as a PDF only.
- 14 March 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (7) , 1000-1002
Autonomic Nervous System Dysregulation and Bone Health in Patients with CKD
An abstract is unavailable. This article is available as a PDF only.